初诊同侧锁骨上淋巴结转移乳腺癌综合治疗疗效

目的 探讨应用新辅助化疗+手术+放疗治疗初诊为锁骨上淋巴结转移乳腺癌患者疗效。方法 回顾分析1999-2013年肿瘤医院收治的65例女性乳腺癌患者的病历资料。全部患者均经初诊病理结果确诊为乳腺癌,且经病理或影像学检查证实为锁骨上淋巴结转移、无远处转移及其他第二原发癌,完整接受术前化疗+手术+术后放疗方案。采用Kaplan-Meier法计算总生存(OS)、无进展生存(PFS)及锁骨上淋巴结复发(SCFR)率,Logrank法检验差异。结果 中位随访时间66个月(6~137个月)。65例患者中5例患者治疗后锁骨上淋巴结复发。全组患者5年SCFR、OS、PFS率分别为9%、72%、50%。术前化疗后锁骨上淋巴结完全缓解是影响OS因素,是否完全缓解患者5年OS率分别为81%和54%(P=0.035)。初诊锁骨上淋巴结大小 (短径≤1 cm、>1 cm)为5年SCFR(分别为0%、21%,P=0.037)和5年OS(分别为86%、56%,P=0.001)的高危因素。结论 对于初诊为锁骨上淋巴结转移的乳腺癌患者,完整接受术前化疗+手术+术后放疗方案治疗后的OS率较高,锁骨上区放疗可获得良好的肿瘤局部控制。     

14例肺原发性黏膜相关淋巴组织淋巴瘤疗效分析

目的 分析肺原发性黏膜相关淋巴组织淋巴瘤的临床特征和预后。方法 回顾分析1999—2012年间14例肺原发性黏膜相关淋巴组织淋巴瘤患者临床资料,其中Ⅰ_E期8例、Ⅱ_E期5例、Ⅲ_E期1例。4例单纯手术治疗,5例术后放疗或化疗,3例化放疗,2例单纯化疗。结果 中位年龄为55岁,男女之比为1∶1.33。中位随访时间为48.3个月。全组患者均存活,3例患者出现治疗失败。全组患者2、4年无进展生存率分别为91%和69%。治疗失败发生在疗后25~37个月,失败部位为双肺、纵隔淋巴结、右肺和脑膜。结论 肺原发黏膜相关淋巴组织淋巴瘤为惰性淋巴瘤,预后良好;临床上可根据患者病变范围和身体状况选择适当治疗。     

Postmastectomy hypofractionation radiotherapy in high-risk breast cancer patients: A phase Ⅰ/Ⅱ clinical trial

目的 探讨乳腺癌改良根治术后大分割放疗的近期疗效和副反应.方法 38例高危乳腺癌患者改良根治术后化疗后,同侧胸壁和锁骨上下放疗43.5 Gy分15次3周完成,观察急性放疗反应发生率和肿瘤的局部区域控制率.结果 中位随访13个月,入组38例患者全部生存,无照射野内复发,远处转移率为13%(5例).5例患者出现3级放射性皮炎,均发生在放疗结束后2～3周.3例患者出现2级放射性肺炎.结论 乳腺癌改良根治术后43.5 Gy分15次3周完成的大分割放疗方案的急性副反应可以接受,近期疗效较好.     

Postmastectomy hypofractionation radiotherapy in high-risk breast cancer patients: A phase Ⅰ/Ⅱ clinical trial

目的 探讨乳腺癌改良根治术后大分割放疗的近期疗效和副反应.方法 38例高危乳腺癌患者改良根治术后化疗后,同侧胸壁和锁骨上下放疗43.5 Gy分15次3周完成,观察急性放疗反应发生率和肿瘤的局部区域控制率.结果 中位随访13个月,入组38例患者全部生存,无照射野内复发,远处转移率为13%(5例).5例患者出现3级放射性皮炎,均发生在放疗结束后2～3周.3例患者出现2级放射性肺炎.结论 乳腺癌改良根治术后43.5 Gy分15次3周完成的大分割放疗方案的急性副反应可以接受,近期疗效较好.     

Postmastectomy hypofractionation radiotherapy in high-risk breast cancer patients: A phase Ⅰ/Ⅱ clinical trial

目的 探讨乳腺癌改良根治术后大分割放疗的近期疗效和副反应.方法 38例高危乳腺癌患者改良根治术后化疗后,同侧胸壁和锁骨上下放疗43.5 Gy分15次3周完成,观察急性放疗反应发生率和肿瘤的局部区域控制率.结果 中位随访13个月,入组38例患者全部生存,无照射野内复发,远处转移率为13%(5例).5例患者出现3级放射性皮炎,均发生在放疗结束后2～3周.3例患者出现2级放射性肺炎.结论 乳腺癌改良根治术后43.5 Gy分15次3周完成的大分割放疗方案的急性副反应可以接受,近期疗效较好.     

早期鼻腔NK/T细胞淋巴瘤局部侵犯特点和靶区定义

目的 分析早期鼻腔NK/T细胞淋巴瘤病例影像学上各个解剖部位受侵概率,为临床靶区设计提供依据.方法 回顾分析1987-2009年经病理证实的222例Ⅰ E、Ⅱ E期鼻腔NK/T细胞淋巴瘤.以影像学为标准,明确邻近受侵器官和结构数目以及淋巴结转移情况.结果 222例患者中64%患者原发肿瘤累及至少一个或多个邻近器官或结构.将鼻腔周围结构依据受侵概率高低分为高危受侵区域(≥40%):筛窦(60%)和上颌窦(55%);中危受侵区域(5%～40%):鼻咽(39%)、鼻背皮肤(22%)、口咽(12%)、眼眶(10%)和硬腭(10%);低危受侵区域(≤5%):蝶窦(3%)、额窦(3%)、软腭(3%)和颅底(1%).全组病例颈部淋巴结转移率为16%(36例).33例Ⅱ E期患者因有影像检查可明确分析颈部淋巴结转移部位,其中最常见受侵区域为颌下或颏下(57%)和上颈部淋巴结(57%).肿瘤局限于一侧鼻腔,对侧颈部淋巴结转移占全部颈淋巴结转移病例(33例)的54%;肿瘤侵犯双侧鼻腔,55%的病例有双侧颈部淋巴结转移.88例超腔Ⅰ期病例未行颈部淋巴结预防照射,颈部淋巴结失败率仅为1%.Ⅰ E期同时合并韦氏环如鼻咽(23例)和口咽(7例)受侵病例,未行颈部淋巴结预防照射,未出现颈部淋巴结失败病例.结论 早期鼻腔NK/T细胞淋巴瘤放疗时应将周围高危解剖结构纳入临床靶区范围,并依据个体侵犯特点考虑中危区域及低危区域的纳入;对颈部淋巴结处理,Ⅰ E期不行颈部预防照射,Ⅱ E期推荐行双侧全颈部照射.

Abstract：

Objective To define the patterns of local extension and nodal involvement in patients with early stage nasal NK/T-cell lymphoma, and to improve the delineation of clinical target volume.Methods Two hundred and twenty-two patients consecutively diagnosed with nasal NK/T-cell lymphoma were reviewed.All patients had stage Ⅰ E/Ⅱ E diseases.CT/MRI images were reviewed to determine the local invasion of adjacent organs or structures and involvement of lymph node.Results 143 of 222(64%) patients had primary tumor extended into adjacent organs or structures from nasal cavity.According to the incidence rates of tumor extension, the involved organs or structures were subclassified into three subgroups:high risk (≥40%):ethmoid sinus (60%) and maxillary sinus (55%);intermediate risk (5%-40%):nasopharynx (39%), skin (22%), oropharynx (12%), orbit (10%), and hard palate (10%);and low risk (≤5%):sphenoid sinus (3%), soft plate (3%),frontal sinus (3%) and skull base (1%).Cervical lymph node metastasis occurred in 16%(36/222) of the patients and these patients were staged as Ⅱ E.Thirty-three patients with stage Ⅱ E disease had available images and were analyzed for the pattern of nodal involvement.Submandibular or submental (57%) and the upper cervical lymph nodes (57%) were the most commonly involved sites of nodal region.For the 24 patients with primary tumor located in the unilateral nasal cavity, 54% presented with contralateral cervical lymph node metastasis.Whereas for the 9 patients with primary tumor located in the bilateral nasal cavity, 57% had bilateral cervical lymph node metastasis.For the 88 patients with extensive stage Ⅰ E disease who did not receive irradiation to the cervical lymph node, only one patient (1%) had disease relapse in cervical lymph node.Furthermore, all patients with disease extended to nasopharynx (n= 23) or oropharynx (n= 8) did not receive prophylactic cervical lymph node irradiation, and none of them developed cervical lymph node relapse.Conclusions The delineation of clinical target volume for early stage nasal NK/T-cell lymphoma should be determined by the risk of involvement of paranasal structures and cervical lymph node.Prophylactic neck irradiation is not recommended for patients with stage Ⅰ disease.